Ian Dunham appointed as Open Targets Director

Open Targets is the public-private partnership on the Wellcome Genome Campus that aims to transform drug discovery through the systematic identification and prioritisation of targets

Ian Dunham appointed as Open Targets Director

Ian Dunham has been appointed Director of Open TargetsOana Stroe
Ian Dunham has been appointed Director of Open Targets

Open Targets has appointed Ian Dunham as its new Director. Ian, a member of Honorary Faculty at the Wellcome Sanger Institute, will focus on the delivery of Open Targets’ established research programme to exploit advances in genetics and genomics for drug target identification and prioritisation. He also aims to increase the use of new approaches to the programme, including single-cell sequencing, CRISPR and artificial intelligence.

Open Targets, launched in 2014, is the public-private partnership between EMBL’s European Bioinformatics Institute (EMBL-EBI), the Wellcome Sanger Institute, GSK, Biogen, Takeda, Celgene and Sanofi. The initiative aims to transform drug discovery through the systematic identification and prioritisation of targets.

“Open Targets is ideally placed for innovation. We have built strong partnerships and established powerful research programmes that exploit advances in genetics and genomics to improve drug target identification. We’re now tapping into the expertise of the Wellcome Genome Campus and our partners to bring other new technologies to our research. Some of the more promising directions include single-cell sequencing, gene editing and artificial intelligence.”

Ian Dunham, Director of Open Targets

Dunham has been the Scientific Director of Open Targets since 2014. He played a pivotal role in establishing the initial research programme and oversaw new bioinformatics and experimental projects initiated by Open Targets. These include experimental projects in oncology, neurodegeneration, immunity and inflammation.

Before joining Open Targets, Dunham held several roles at EMBL-EBI, and his research areas included genome-wide mapping of regulatory elements and chromatin state in the human genome. He was also an integral part of the NHGRI ENCODE project, which focused on identifying all functional regions of the human genome, regardless of whether they formed genes or not. Dunham’s interest in mapping the human genome has been a recurring theme throughout his career.

“Open Targets is an excellent example of how computational and experimental researchers from different backgrounds and sectors can collaborate to improve drug discovery. I am delighted to see Ian stepping up to lead the collaboration. His expertise in genetics, genomics and his involvement with the project from its inception will be invaluable in developing the collaboration even further.”

Rolf Apweiler, Interim Head of Open Targets and Joint Director of EMBL-EBI

Notes to Editors
Selected Websites
How are drugs designed and developed?FactsHow are drugs designed and developed?
Producing a new drug is an expensive and time-consuming process that is subject to extensive regulation.

What is pharmacogenomics?FactsWhat is pharmacogenomics?
Pharmacogenomics is the tailoring of drug treatments to people’s genetic makeup, a form of ‘personalised medicine’.

Pharmacogenomics and cancerStoriesPharmacogenomics and cancer
Pharmacogenomics is a specific kind of genetic testing that offers key advantages for doctors trying to choose the best drugs for their patients. 

Adverse drug reactionsStoriesAdverse drug reactions
An adverse drug reaction is when a medication given as instructed and at a normal dose has an unwanted or harmful effect on a patient. 

Contact the Press Office

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Emily Mobley, Media Officer

Tel +44 (0)1223 496 851

Wellcome Sanger Institute,
CB10 1SA,

Mobile +44 (0) 7900 607793

Recent News

Sanger Institute researcher, Henry Lee-Six, wins Dr Falk Pharma/Guts UK essay prize
Medical student working in the Cancer Genome Project wins prize for colon cancer research
2019 Chief Medical Officer’s Report published
Sanger Institute researchers contribute to Professor Dame Sally Davies' eleventh annual report
Multi-drug resistant malaria spreading in Asia
Study reveals importance of ongoing genomic surveillance for malaria control strategies